Shanghai Langsheng Biotechnology

Langsheng Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative gene therapies for ophthalmic diseases. The company leverages its proprietary adeno-associated virus (AAV) vector platform to create treatments for inherited retinal dystrophies and common ocular conditions like wet age-related macular degeneration. Its lead candidate, LX101, targets RPE65-mediated retinal degeneration and was among the first AAV gene therapies to enter clinical trials in China. Langsheng Biotech is backed by prominent investors including Qiming Venture Partners and Lilly Asia Ventures, aiming to address significant unmet medical needs in the field of ophthalmology. The company maintains integrated capabilities spanning R&D, clinical development, and GMP manufacturing.